Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Fever × dabrafenib × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 27 Neoplasms 9 Thyroid Neoplasms 5 Thyroid Carcinoma, Anaplastic 5 Brain Neoplasms 5 Multiple Myeloma 3 Glioma 3 Carcinoma, Non-Small-Cell Lung 3 Skin Neoplasms 2 Neoplasm Metastasis 2 Hematologic Neoplasms 2 Glioblastoma 2 Colorectal Neoplasms 2 Astrocytoma 2 Ameloblastoma 2 Thyroid cancer, follicular 1 Thyroid cancer, Hurthle cell 1 Thyroid Cancer, Papillary 1 Solid Tumor 1 Rare Malignant Neoplasm 1 Oligodendroglioma 1 Nonseminomatous germ cell tumor 1 Neurocytoma 1 Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Locally Advanced Thyroid Gland Carcinoma 1 Leukemia, Hairy Cell 1 Gastrointestinal Stromal Tumors 1 Ganglioneuroma 1

Interventions

trametinib 1 pegfilgrastim 1 ofatumumab 1 dabrafenib 1 Lenalidomide 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Doxorubicin 1 Docetaxel 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01972347 2025-12-16

Neo Combi

Melanoma Institute Australia

Phase 2 Active not recruiting

Fever, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡